News

InnoCore strengthens microsphere technology

InnoCore Technologies, member of the PolyVation Group, announced strengthening the collobaration with Nanomi for the development of advanced monodisperse biodegradable microsphere-based controlled release formulations. Under the collaboration the companies will jointly offer their combined proprietary SynBiosys and Monosphere technologies to the market as a powerful platform technology for the sustained delivery of biotherapeutics.

SynBiosys is an advanced biodegradable polymeric drug delivery system. Its biodegradability, proven biological safety and easily adjustable release characteristics make SynBiosys an excellent drug delivery platform for the controlled release of the full spectrum of active compounds. SynBiosys-based depot formulations do not suffer from accumulation of acidic degradation products in the polymer matrix, as is the case with PLGA-based depots. This enables the sustained release of structurally intact and biologically active therapeutic peptides and biotech-derived compounds for periods ranging from several days to more than half a year. The total control of particle size provided by the Monosphere technology allows for minimally invasive and less painful injection through very thin needles. This aspect is not only beneficial in subcutaneous and intramuscular administration, but especially appreciated in more advanced delivery routes such as intra-articular or intraocular injection. It even enables novel delivery strategies such as site-specific drug delivery to organs through capillary embolization. Furthermore, monodisperse microspheres provide reduced particle-related immunoactivation due to the absence of undersized microspheres. Together with its robustness, reproducibility and straightforward scalability these features make Monosphere technology a valuable asset for the development and manufacture of microspheres for injectable depots. This value is already underlined by three of the top ten big pharma companies.